Cochlear (ASX: COH) faces a shareholder class action over its FY26 profit forecast, just as its Nexa rollout, fully implantable trials and a November investor day shape the recovery story.
Cochlear’s share price slump reflects profit downgrades, slowing growth, weak global demand, and macro pressures. The stock is down sharply, but a lasting bottom likely depends on stabilising earnings and clearer signs of demand recovery.
